AstraZeneca PLC (NYSE:AZN) Expected to Announce Quarterly Sales of $11.14 Billion

Brokerages expect that AstraZeneca PLC (NYSE:AZNGet Rating) will announce sales of $11.14 billion for the current quarter, Zacks reports. Two analysts have issued estimates for AstraZeneca’s earnings, with estimates ranging from $11.11 billion to $11.17 billion. AstraZeneca posted sales of $7.32 billion during the same quarter last year, which would indicate a positive year over year growth rate of 52.2%. The company is scheduled to report its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that AstraZeneca will report full year sales of $44.00 billion for the current financial year, with estimates ranging from $43.69 billion to $44.25 billion. For the next fiscal year, analysts expect that the business will report sales of $47.01 billion, with estimates ranging from $46.19 billion to $47.42 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow AstraZeneca.

Separately, initiated coverage on shares of AstraZeneca in a research report on Thursday, March 31st. They issued a “hold” rating for the company.

AZN opened at $66.40 on Friday. AstraZeneca has a 1-year low of $52.74 and a 1-year high of $71.70. The company has a 50-day moving average of $64.31.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.